AUSTIN, Texas, July 18, 2018 (GLOBE NEWSWIRE) -- Vermillion, Inc. (Nasdaq: VRML ), a bio-analytical solutions company focused on gynecologic disease, today announced that it will report financial results for the second quarter and six months ended June 30, 2018 on Thursday, August 9, followed by an investor conference call and webcast at 4:30 p.m. Eastern Time.

Thursday, August 9 th @ 4:30pm Eastern Time Domestic:                   800-239-9838 International:              323-794-2551 Conference ID:           5791297 Webcast:                    http://public.viavid.com/index.php?id=130234

Replays, Available through August 23 rd : Domestic:                   844-512-2921 International:              412-317-6671 Replay PIN:                5791297

About Vermillion Vermillion, Inc. (NASDAQ: VRML ) is dedicated to the discovery, development and commercialization of novel high-value diagnostic and bio-analytical solutions that help physicians diagnose, treat and improve outcomes for patients. Vermillion, along with its prestigious scientific collaborators, has programs in gynecologic disease.

The company’s lead diagnostic, OVA1®, is a blood test for pre-surgical assessment of ovarian tumors for malignancy, using an innovative algorithmic approach. As the first FDA-cleared, protein-based In Vitro Diagnostic Multivariate Index Assay, OVA1 represents a new class of software-based diagnostics. For additional information, including published clinical trials, visit www.vermillion.com.

Investor Relations Contact: Ashley R. Robinson LifeSci Advisors, LLC Tel 617-775-5956 Arr@LifeSciAdvisors.com